Developing a Molecular Roadmap of Drug-Food Interactions by Kouskoumevakaki, IK et al.
Title Developing a Molecular Roadmap of Drug-Food Interactions
Author(s) Jensen, JK; NI, Y; Panagiotou, I; Kouskoumevakaki, IK
Citation PLoS Computational Biology, 2015, v. 11 n. 2, p. e1004048
Issued Date 2015
URL http://hdl.handle.net/10722/208753
Rights Creative Commons: Attribution 3.0 Hong Kong License
RESEARCH ARTICLE
Developing a Molecular Roadmap of Drug-
Food Interactions
Kasper Jensen1, Yueqiong Ni2, Gianni Panagiotou2*, Irene Kouskoumvekaki1*
1 Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark, 2 School of
Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong
* gipa@hku.hk, irene@cbs.dtu.dk
Abstract
Recent research has demonstrated that consumption of food -especially fruits and vegeta-
bles- can alter the effects of drugs by interfering either with their pharmacokinetic or phar-
macodynamic processes. Despite the recognition of such drug-food associations as an
important element for successful therapeutic interventions, a systematic approach for identi-
fying, predicting and preventing potential interactions between food and marketed or novel
drugs is not yet available. The overall objective of this work was to sketch a comprehensive
picture of the interference of* 4,000 dietary components present in*1800 plant-based
foods with the pharmacokinetics and pharmacodynamics processes of medicine, with the
purpose of elucidating the molecular mechanisms involved. By employing a systems chemi-
cal biology approach that integrates data from the scientific literature and online databases,
we gained a global view of the associations between diet and dietary molecules with drug
targets, metabolic enzymes, drug transporters and carriers currently deposited in Drug-
Bank. Moreover, we identified disease areas and drug targets that are most prone to the
negative effects of drug-food interactions, showcasing a platform for making recommenda-
tions in relation to foods that should be avoided under certain medications. Lastly, by inves-
tigating the correlation of gene expression signatures of foods and drugs we were able to
generate a completely novel drug-diet interactome map.
Author Summary
Vegetables and fruits that are otherwise considered beneficial to our health can have seri-
ous consequences in medical care. Interference of plant-based foods with drug perfor-
mance and pharmacological activity may potentially contribute to an increased risk of side
effects or treatment failure. A well-known example of a drug-food interaction, the inhibi-
tory effect of grapefruit juice on cytochrome P450, results in increased bioavailability of
drugs such as felodipine, cyclosporine and saquinavir, which could lead to drug toxicity
and poisoning. Although the importance of drug-food interactions has long been known,
a systematic approach to identify, predict and prevent potential interactions between food
and drugs has not yet been established. This work sets the ground for the understanding of
the key molecular mechanisms of drug-food interactions with the scope to optimize
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therapeutic strategies and improve patient care. We tackle this problem using NutriChem,
a database we have recently developed with information from the scientific literature and
online databases related to natural compound origin and bioactivity. This systems chemi-
cal biology approach provides the basis for the identification and study of the substances
in plant-based foods that affect the human proteins that are relevant for the pharmacoki-
netics and pharmacodynamics of current medicine.
Introduction
Drugs and plant-based foods (i.e. fruits, vegetables and beverages derived from them, referred
to simply as “food” throughout the rest of the document) manifest an intricate relationship in
human health and have a complementary effect in disease prevention and therapy. In many dis-
eases, such as hypertension, hyperlipidemia, and metabolic disorders, dietary interventions play
a key part in the overall therapeutic strategy [1]. But there are also cases, where food can have a
negative impact on drug therapy and constitute a significant problem in clinical practice. Recent
research has demonstrated that foods are capable of altering the effects of drugs by interfering
either with their pharmacokinetic or pharmacodynamic processes [2]. Pharmacokinetics in-
cludes the Absorption, Distribution, Metabolism and Excretion of drugs, commonly referred to
jointly as ADME. Pharmacodynamic processes are related to the mechanisms of drug action,
hence the therapeutic effect of drugs; interactions between food and drugs may inadvertently
reduce or increase the drug therapeutic effect [3]. Until not long ago, our knowledge about
drug-food interactions derived mostly from anecdotal experience, but recent scientific research
can demonstrate examples, where food is shown to interfere with the pharmacokinetics and
pharmacodynamics of drugs via a known, or partially known, mechanism of interaction: an in-
hibitory effect of grapefruit juice on Cytochrome P450 isoenzymes (e.g. CYP3A4) that leads to
increased bioavailability of drugs e.g. felodipine, cyclosporin and saquinavir and potential
symptomatic toxicity has been reported [4]; green tea reduces plasma concentrations of the β-
blocker nadolol, possibly due to inhibition of the Organic Anion Transporter Polypeptide 1A2
(OATP1A2) [5]; activity and expression of P-glycoprotein (P-gp), an ATP-driven efflux pump
with broad substrate specificity, can be affected by food phytochemicals, such as quercetin,
bergamottin and catechins, which results in altered absorption and bioavailability of drugs that
are Pgp substrates [6]; an antagonistic interaction of anticoagulant drug warfarin with vitamin
K1 in green vegetables (e.g. broccoli, Brussels sprouts, kale, parsley, spinach), whereby the
hypoprothrombinemic effect of warfarin is decreased and thromboembolic complications may
develop [2]; sesame seeds have also been reported to negatively interfere with the tumor-inhibi-
tory effect of Tamoxifen [7]. Judging from the examples above, under most in vitro drug-food
interaction studies, food is either treated as one entity, or the study focuses on few, well-studied
compounds, such as polyphenols, lipids and nutrients.
Our main hypothesis in the current work is that the interference of food on drug pharmaco-
kinetic or pharmacodynamic processes is mainly exerted at the molecular level via natural
compounds in food (i.e. phytochemicals) that are biologically active towards a wide range of
proteins involved in drug ADME and drug action. The hypothesis is certainly supported by the
large number of natural compounds that have reached the pharmacy shelves as marketed
drugs. Hence, the more information we gather about these natural compounds, such as molec-
ular structure, experimental and predicted bioactivity profile, the greater insight we will gain
about the molecular mechanisms dictating drug-food interactions, which will help us identify-
ing, predicting and preventing potential unwanted interactions between food and marketed or
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novel drugs. However, unlike drug bioactivity information that has already been made available
for system-level analyses via databases such as ChEMBL (www.ebi.ac.uk/chembldb/) [8] and
DrugBank (http://www.drugbank.ca/) [9], biological activity data and origin information of
natural compounds are scarce and unstructured. To this end, we have developed a database
generated by text mining of 21 million MEDLINE abstracts that pairs plant-based foods with
the natural compounds they contain, their experimental bioactivity data and related human
disease phenotypes [10,11]. In the present work, we are exploring this resource for links be-
tween the natural compound chemical-space of plant-based foods with the drug target space.
By integrating protein-chemical interaction networks and gene expression signatures we pro-
vide a methodology for understanding mechanistically the effect of eating behaviors on thera-
peutic intervention strategies.
Results
The drug-like chemical space of plant-based diet
In order to sculpt the chemical space of the natural compounds included in plant-based
foods, we resorted to our recently developed resource NutriChem (www.cbs.dtu.dk/services/
NutriChem-1.0) [11], which includes 1,772 plant-based foods associated by text-mining with
*8,000 unique natural compounds (a.k.a. phytochemicals). Experimental bioactivity informa-
tion exists in ChEMBL for less than half of these food compounds (Fig. 1A). Within this clus-
ter, we identified 463 phytochemicals with bioactivity at the range of drug activity against 207
drug targets (i.e. targets related to drug pharmacodynamics), as well as 18 enzymes, 7 trans-
porters and 3 carriers, ADME-relevant targets as deposited in DrugBank v.3. As shown in
Fig. 1B, foods that are routinely part of our diet, such as strawberry, tomato, celery and maize,
are involved via their bioactive phytochemicals in a high number of interactions with proteins
within these 4 categories.
Ginger’s phytochemical profile appears as the most biologically active, interacting in total
with 151 proteins, most of which associated with drug pharmacodynamics. This molecular
level evidence of food-drug interactions is also in line with the information from the scientific
literature assembled in NutriChem, which links ginger with 87 different human disease pheno-
types. It should be pointed out that the 15 highly interacting foods shown in the figure are not
necessarily the best characterized in terms of number of assigned phytochemicals. The number
of bioactive phytochemicals in them ranges from 18 for mango to 42 for camellia-tea, while
foods like licorice and rhubarb, for example, contain similar number of bioactive compounds
(33 and 24 respectively) without, however, interacting with as many proteins within these 4
categories. Thus, the above result is not the outcome of data incompleteness biases in the scien-
tific literature, but rather points towards specific structural characteristics of phytochemicals
dictating drug-food interactions.
In order to further hone in the dietary habits that augment the impact on drug efficiency,
we created a network that relies on the number of unique protein interactions shared between
different foods. As shown in Fig. 1C several sub-networks of foods interact with the same pro-
tein space; a property that could be taken into account when drugs targeting these proteins are
prescribed. For example, safflower, lettuce and garlic form a small sub-network that shares
more than 55 proteins with experimental activity data involving their phytochemicals. The
most broadly active food group consists of guava, mango, strawberry, beansprout, camellia-tea,
swede and tomato, with the average number of shared interacting proteins being more than 70.
Papaya, orange, dill, tangerine, cress and chili pepper, along with a few more foods, form an
isolated module interacting with a separate protein target space. In all food clusters of Fig. 1C it
is apparent that there is no phenotypic or higher level taxonomic characteristic of the foods
Systems-wide Drug-Food Interactions
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that could be used to predict the shared interactions with the therapeutic protein space; this
pattern has emerged from similarities in their phytochemical space.
Effect of drug-food interactions on drug pharmacodynamics and
pharmacokinetics
To get an insight of the pharmacodynamics processes that are mostly affected by the bioactive
phytochemicals of our diet, we zoomed in on the interactions with drug targets. Comparing
Fig. 2A, which presents the foods with the highest number of interactions with targets involved
in drug pharmacodynamics, with Fig. 1B that relies on all protein interactions of a drug (target,
transporter, carrier and metabolic enzyme), we notice that rice and avocado have replaced
maize and licorice in the top-15 list. Furthermore, categorizing drug targets based on their
human disease association, demonstrates the broad spectrum of disease treatments that may be
Fig 1. A molecular based view of drug-food interactions. (A) Number of plant-based food compounds in our database with (blue) and without (green)
experimental bioactivity information in ChEMBL. (B) The plant-based foods with the most interactions to drug targets, carriers, transporters and enzymes.
The plot shows the 15 most interacting foods within these 4 categories. (C) Network of foods that interact with the same drug target proteins. Node size
reflects the number of bioactive compounds (phytochemicals) and interacting proteins for a given food. Edge width reflects the number of common interacting
proteins between two foods. The nodes with the highest number of bioactive phytochemicals and interacting proteins are shown in blue. The edges with the
highest number of common interacting proteins are shown in black. For visualization purposes, the top 5 edges for each node are shown on the network,
while the complete data are provided as supplementary material (S1 Table).
doi:10.1371/journal.pcbi.1004048.g001
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affected by dietary habits. As shown in Fig. 2A, drug targets for 13 disease categories, ranging
from cancer, neurological and cardiovascular to infectious and immunological diseases, could
be potentially altered by food components. Another observation from Fig. 2A, not surprising
Fig 2. Drug-food interactions affecting drug pharmacodynamics. (A) The plot shows the plant-based foods with the highest number of interactions with
drug targets and their associated human disease classification. (B) The number of drug targets affected by food, annotated to different biological systems.
The expected number of targets in each biological category was calculated as: exp = (tpc / tdt) * tpa, where, tpc: the total number of drug targets from
DrugBank in a biological category, tdt: the total number of drug targets in all biological categories (1,806 proteins) and tpa: the total number of drug targets
that participate in drug-food interactions based on our analysis (186 proteins). (C) Networks of drug targets affected by food, per human disease class, shown
for the 6 disease classes with the highest number of drug targets involved in food interactions. Two drug targets are connected when there are at least 3 drug-
food pairs with biological activity against both proteins. The numbers inside the pie correspond to the total number of drug targets under each disease class
that are affected by food. For visualization purposes, we show only the top 5 edges for each node, while the complete data are provided as supplementary
material (S2 Table).
doi:10.1371/journal.pcbi.1004048.g002
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due to the well-known protective role of plant-based diet against cardiovascular and gastroin-
testinal diseases, is that their drug targets are highly associated with phytochemical activity.
Furthermore, looking into the association between food and drug targets at a biological process
level reveals a wide range of functions that are targeted by food components (Fig. 2B). Never-
theless, our analysis points to that foods “show a preference” towards a specific drug target
space that is significantly overrepresented (Student’s t-test, p<0.05) with proteins involved in
signal transduction, immune system and developmental processes (Fig. 2B).
Having identified the foods that interact the most with drug targets and the biological pro-
cesses that these targets participate in, we took a step further and zoomed into individual pro-
teins. We constructed a network for each disease category (Fig. 2C), which links drug targets
based on the drug-food pairs they share. For example in cancer, drug targets of the carbonic an-
hydrase family are tightly connected, as they share a large number of drug-food pairs. Looking
into the neurological diseases we could identify a tight connection between the kappa- and
delta- type opioid receptors, while for cardiovascular diseases a network of the 5-hydroxytryp-
tamine receptors is highly targeted by the same drug-food pairs. Naturally, since many of the
drug targets are shared between different disease classes, some of these networks were observed
in more than one disease category. Nevertheless, similarly to our observations above at the bio-
logical process level, our analysis here revealed that drugs developed for certain protein targets
are more prone to be affected by diet than others.
In order to explore the identified drug-food interactions at a molecular level, we selected case
studies from 5 disease categories and highlighted the food components with the highest binding
affinity to the drug targets. As shown in Fig. 3, aromatase, a protein targeted by 5 anticancer
drugs (Anastrozole, Testolactone, Exemestane, Letrozole and Aminoglutethiumide) is also tar-
geted by naringenin (IC50 = 2.9nM), a compound found in licorice, beansprout and maize,
among others. Kaempferol, present in lychee, onion, strawberry and other common foods has a
high binding affinity (IC50 = 3.0nM) for the epidermal growth factor receptor, target of Lapati-
nib, Gefitinib, Vandetanib and Erlotinib anticancer drugs. For neurological diseases, serotonin,
present in sunflower, potato and tomato interacts strongly (Ki = 1.1nM) with the 5-hydroxytryp-
tamine receptors targeted by several drugs (e.g. Loxapine, Buspirone, to name a few), whereas,
aporphine, present in poppy-seed, binds to the D(2) dopamine receptor (Ki = 527nM), target of
Ofremoxipride, Sulpiride and other drugs (Fig. 3). P-hydroxybenzoic acid, a compound naturally
found in coconut, currant, sprouted lentil, swede and other foods, binds strongly (Ki = 920nM)
to carbonic anhydrase, target of the cardiovascular drug Trichlormethiazide. Lastly, resveratrol, a
compound that earned its prophylactic reputation against cardiovascular diseases due to its pres-
ence in red wine (represented by grape in Fig. 3), was found in our analysis to interfere with the
activity of several drugs (Diclofenac, Raloxifene, etc.) that target either the estrogen receptor or
prostaglandin G/H synthase 2 (involved in musculoskeletal diseases).
Turning our focus to the effects of diet on the pharmacokinetics of drugs, we studied the in-
teractions of phytochemicals with proteins involved in drug ADME. Fig. 4 illustrates the corre-
sponding drug-food interaction networks for metabolic enzymes and transporters, where
apigenin, quercetin, naringenin, resveratrol and nicotinic acid are the food components with
the strongest binding affinities. These compounds are found in more than 40 foods; hence, a
complete understanding of their interaction profile with drug ADME proteins is of utmost im-
portance. For acetylcholinesterase and cholinesterase, two proteins involved in the metabolism
of several drugs, e.g. Neostigmine (myasthenia gravis), Isoflurophate (glaucoma), Donepezil
(dementia), Galantamine (dementia), the binding affinity of the phytochemicals quercetin and
apigenin is lower than the one of the drugs, but still in the range of measured activities for
these metabolic targets. In other cases, such as aromatase, involved in the metabolism of Ana-
strozole, Letrozole, Exemestane and Aminoglutethimide, drugs used against breast cancer, we
Systems-wide Drug-Food Interactions
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encounter bioactive food components with stronger activities. Naringenin, a compound found
in licorice, sugar pea, guava and others, has a binding affinity of IC50 = 1000nM against aro-
matase, comparable with the actual drug’s. Similarly, the ribosyl-dihydronicotinamide dehy-
drogenase, involved in the metabolism of primaquine, is targeted from resveratrol with binding
affinity higher than that of the respective drug (IC50 = 450nM) (Fig. 4). Resveratrol interacts as
well with the multidrug resistance protein 1, involved in the transport of several cancer drugs
(Tamoxifen, Vinblastine) and other types of drugs, such as the antiretroviral drug Nelfinavir or
Haloperidol an antipsychotic medication.
Evaluation of drug-food interactions through their gene expression
signatures
Despite a thorough investigation of the interaction network formed by the bioactive compound
space of diet and the drug activity space, the obtained results of possible drug-food interactions
Fig 3. Disease-specific networks of drug-food interactions on proteins affecting drug pharmacodynamics. Node shape denotes drug target (circle),
drug (triangle) and food (diamond). Edge color highlights the food compound (phytochemical) that shows the highest binding activity to the effect target. Edge
width denotes the biological activity (Ki, IC50) and ranges between 1nM to 1000 nM. For visualization purposes, only 3 drugs and 3 foods with the highest
biological activities are shown for each drug target, while the complete data are provided as supplementary material (S3 Table).
doi:10.1371/journal.pcbi.1004048.g003
Systems-wide Drug-Food Interactions
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004048 February 10, 2015 7 / 15
heavily rely on the available data related to the phytochemical content of food as well as the ac-
tivity of these molecules on human proteins. To overcome the barrier of data incompleteness
we compared the gene expression signatures of diet with the ones of FDA approved drugs,
looking for correlated and anti-correlated profiles. The statistical analysis was performed using
the Connectivity Map [12] which includes gene expression signatures from 1,309 compounds,
both FDA-approved drugs and bioactive compounds. We retrieved gene expression data for
9 foods that are linked in NutriChem with 390 unique compounds; these 390 compounds are
chemically similar to both CMap compounds as well as FDA approved drugs currently present
in DrugBank (Fig. 5A). We could also retrieve 5,171 protein targets (direct and indirect) of
these compounds, where “disease” is the most enriched pathway with 538 protein targets in-
volved (Fig. 5B). Other significantly enriched pathways include cell cycle, developmental biolo-
gy and apoptosis. Looking into the gene expression profiles of these 9 foods, we noticed that
collectively 9,072 genes appear significantly differentially expressed (FDR corrected moderated
t-test, p<0.05) between the control samples and the diet interventions. Interestingly, when
these gene targets were further analyzed, the biological processes that were found significantly
Fig 4. Networks of drug-food interactions affecting drug pharmacokinetics.Node shape denotes enzyme/transporter (circle), drug (triangle) and food
(diamond). Edge color highlights the phytochemical with the highest binding activity to the protein target. Edge width denotes the biological activity (Ki, IC50)
and ranges between 1nM to 1000 nM. For visualization purposes, only 3 drugs and 3 foods with the highest biological activities are shown for each protein
target, while the complete data are provided as supplementary material (S4 Table).
doi:10.1371/journal.pcbi.1004048.g004
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enriched have a high similarity with the protein space targeted by the phytochemicals (Fig. 5B
vs. Fig. 5C). However, what we also observed was that from the 5,171 proteins targeted by the
food components, only 2,653 were found in the significantly differentially expressed (DE) gene
list. In our attempt to understand the reasons behind this discrepancy we selected a sub-set of
56 food phytochemicals that were targeting proteins from both groups; the ones that showed a
significantly different expression level and the ones that did not (non-DE). We compared the
binding affinity for those compounds having both DE targets and non-DE targets as well as the
protein connectivity of their targets. While the protein connectivity analysis did not yield a sta-
tistically significant difference between the two groups, the IC50 values were significantly lower
Fig 5. Comparative analysis of food and drug gene expression signatures. In total 9 high-quality gene
expression signatures of plant-based foods could be retrieved (A) Chemical similarity comparison between
390 phytochemicals, the bioactive compounds present in ConnectivityMap (1,309) and FDA-approved drugs
in DrugBank. (B) Pathway enrichment analysis of the proteins targeted (directly and indirectly, see Materials
and Methods) by the phytochemicals. (C) Pathway enrichment analysis of the 9,072 genes that were found
collectively significantly differentially expressed in the pair-wise comparisons of each food with the respective
control. (D) Drug-food interactions based on the food gene expression signatures submitted to CMap. Food
(yellow nodes) and drug (squares with different colors based on disease classification) are connected if they
show a correlated (grey edge) or anti-correlated (orange edge) gene expression signature. The width of the
edge indicates the significance level of the observed correlation.
doi:10.1371/journal.pcbi.1004048.g005
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(Wilcoxon rank-sum test p value< 0.05) for the compounds targeting the non-DE group
of genes.
Using as input the gene expression signatures of each of the 9 foods, we retrieved 133 CMap
compounds, of which, 46 FDA approved drugs that have a significant correlated or anti-
correlated profile (Fig. 5D). These 46 FDA approved drugs were further mapped to disease cat-
egories showing that mostly drugs used against infectious diseases (13), cancer (9) and neuro-
logical diseases (9) induce a gene expression signature that can be either enhanced or reversed
by diet. In the drug-food interaction network shown in Fig. 5D, broccoli has the highest num-
ber of connections with drugs. Interestingly, all connections between broccoli and drugs are
correlation-based, most of which display strong correlation coefficients. This finding sheds
some additional light-from a mechanistic point of view- on the well-known beneficial effect of
broccoli on human health. Orange and garlic induce a gene expression profile that is highly
correlated with drugs used in cancer (Carmustine, Mercaptopurine) and reproductive disor-
ders (Dydrogesterone, Diethylstilbestrol); orange specifically, is highly correlated with the ac-
tivity of Orciprenaline (drug against a metabolic disease), Pyrimethamine (drug against an
infectious disease) and Hydroxyzine (drug against a neurological disease). One notable case is
olive oil; olive oil induces a gene expression signature highly anti-correlated with the anticancer
drugs Mitoxanthrone, Irinotecan and Daunorubicin. Mitoxanthrone and Daunorubicin are
typically used against leukemia, where olive oil has not demonstrated any beneficial effect. Iri-
notecan, on the other hand, is a drug used against colon cancer, a disease which several studies
suggest that olive oil has actually a prophylactic effect on.
The analysis presented here should serve as a proof-of-concept comparison of the global
gene expression responses induced by drugs and foods. The food gene expression signatures
used here come from multiple research groups, diverse experimental designs and different tis-
sues from animal models or human subjects, which may influence the correlation with the
drugs. Nevertheless, the significant reduction of next generation sequencing cost is expected to
positively influence nutritional studies as well, and allow transcriptome profiling of diets in a
high throughput manner that could then be analyzed using our approach for possible interac-
tions with drugs.
Discussion
Plant-based therapies have been used for a variety of symptoms for thousands of years while re-
cently there has been a drastic growth in the consumption of herbs and natural supplements
with health benefits. In relation to AIDS and cancer patients especially, two life-threatening
diseases where classical drug treatment does not always have a guaranteed effect, the use of
both multiple prescription drugs and herbal supplements is very prevalent [13,14]. Given that
components of herbs and natural supplements interact with human proteins in a similar man-
ner as drugs, there is a high potential for altering drug efficiency. Furthermore, phytochemicals
are abundant in our diet and have been shown in vitro to influence human proteins and cell-
cultures. Several have demonstrated activity against the same proteins as drugs, and thus, po-
tentially influence their pharmacokinetics and pharmacodynamics behavior when consumed
concomitantly. In the example of sesame seed that has been reported to negatively interfere
with the tumor-inhibitory effect of Tamoxifen [7], the protein responsible for the therapeutic
effect of Tamoxifen is the estrogen receptor (P03372), which is also targeted by a number of
different bioactive phytochemicals present in sesame, including beta-sitosterol [15][16]. Que-
rying NutriChem for beta-sitosterol, we encounter it as phytochemical component of guava,
onion, pomegranate, turnip, fennel, celery and kiwifruit—all common foods of our diet that
could also be potentially involved in interactions with Tamoxifen and negatively affect its
Systems-wide Drug-Food Interactions
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therapeutic activity. As another example, health professionals recommend to patients under
medication against high blood pressure to avoid consumption of licorice (http://www.ehow.
com/list_5798754_foods-avoid-taking-beta_blockers.html). The mechanism of this drug-food
interaction is not yet clarified, although it has been occasionally attributed to the presence of
glycyrrhizin. Our analysis points though towards the phytochemical liquiritin contained in lic-
orice. Liquiritin has been found to interact with the beta-2 adrenergic receptor (P07550; Bioas-
say CHEMBL1738166), which is the primary target of beta-blockers, such as Penbutolol, a
drug against hypertension.
The overall objective of this work was to gain knowledge on the interference of food phyto-
chemicals with the pharmacokinetics and pharmacodynamics processes of medicine, with the
purpose of elucidating the molecular mechanisms involved. To the best of our knowledge this
is the first time of such a scale integration of data from the literature and online, publicly avail-
able databases coupled with gene expression analysis, for studying the effect of natural bioac-
tive compounds from foods on proteins related to drug bioavailability and therapeutic effect.
Our analysis brings into sight that cancer-related proteins are highly targeted by dietary mole-
cules; since cancer is still one of the most deadly diseases, patients are willing to follow alterna-
tive therapeutic approaches, most often concomitantly with standard drug treatment, such as
adopting a “healthy diet” that usually consists of fruits and vegetables. While this approach
could be beneficial prior the onset of disease as a preventive measure, it should perhaps be
adopted with caution when a patient is under drug therapy, as it may interfere with the thera-
peutic effect of the drug.
The novelty of the platform presented here is that it takes into account the global effects of
food, propelled by its rich natural compound content, increasing the level of confidence of
the scientific community and medical professionals when making recommendations for
foods that should be avoided under certain medications. We illustrate that ignoring the com-
plete phytochemical content of a food and focusing on a couple of “hot”molecules, a strategy
widely applied in traditional food research, will never reveal the true magnitude of drug-food
interactions. Furthermore, we identify clusters of foods that target the same therapeutic
space as drugs, a property that could potentially increase the chances for severe alterations
of the drug activity if these foods are consumed concomitantly. We also point out a large
number of food components that are potentially involved in yet not documented drug-food
interactions supporting the notion that ignoring the complete chemical content of a food is
a missing link for obtaining a holistic view of the effect of diet. From a methodological point
of view we believe that including the actual bioactivity values of the phytochemicals against
proteins related to drug bioavailability and therapeutic effect allowed us to go beyond a sim-
ple enumeration of interactions to a more comprehensive and possibly accurate mapping
of food-drug associations. Our food-drug interaction network reveals that therapeutic inter-
ventions for every disease category can be potentially affected to some degree by diet, even
though specific disease areas, e.g. cancer and neurological diseases, are most prone to the
negative effects of drug-food interactions than others. Lastly, we believe that we have demon-
strated with several examples the power of a systems-level analysis to answering the two
most important questions for patients and clinicians: (1) which foods should be potentially
avoided from a patient under treatment, and (2) which is the underlying mechanism behind
these drug-food interactions. However we should also keep in mind that, since many of the
food compounds that are strong binders to proteins are very common in our diet, it will
certainly be a daunting task to actually design diets that will not include any such com-
pounds. Thus, adding in the network analysis the actual concentration in food of each bioac-
tive compound would give a more accurate picture of the extent and severity of these drug-
food interactions.
Systems-wide Drug-Food Interactions
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Materials and Methods
The food-drug interaction space
The plant-based food compounds and their chemical structures were retrieved from Nutri-
Chem 1.0 [11]. FDA-approved small molecule drugs were retrieved from DrugBank v.3
(http://drugbank.ca/ downloaded on Jan 12th, 2014). Food compounds and drugs were mapped
to their protein interactions using ChEMBL v.16 (http://www.ebi.ac.uk/chembl/ downloaded
on Sept 9th, 2013). Binding activities were retrieved from ChEMBL Bioassays. Protein targets
were categorized into “Drug target”, “Enzyme”, “Transporter” and “Carrier”, following the
DrugBank categorization. For a food compound to be considered active against a protein tar-
get, it has to bind within the range of the drugs targeting the same protein. For proteins, for
which the binding activity of drugs was unknown, the binding activity of the food compound
was compared to the mean value of the binding activities for proteins from the same category
(i.e. drug target, enzyme, transporter or carrier). Drug protein targets were mapped to disease
categories using the Therapeutic Target Database (http://bidd.nus.edu.sg/group/cjttd/ down-
loaded on Sept 9th, 2013) [17] and the Human Disease Ontology [18]. Disease categories were
selected at the third level of the human disease ontology. Drug proteins were assigned to bio-
logical systems using Reactome (http://www.reactome.org).
Gene expression signature comparison
Chemical similarity between phytochemicals, CMap bioactive compounds and FDA-ap-
proved drugs. SMILES strings of phytochemicals were retrieved from PubChem [19], while
SMILES of the CMap bioactive compounds and FDA-approved small molecule drugs were re-
trieved from Connectivity Map build 02 [12] and DrugBank 3.0 [9], respectively. Based on the
chemical structures, molecular and physical descriptors were calculated for each compound
using the RDKit plugin (http://www.rdkit.org) in KNIME [20], including a 1024-bit Morgan
circular fingerprint, Topological Polar Surface Area (TPSA), octanol/water partition coefficient
(SlogP), Molecular Weight (MW), number of Lipinski hydrogen bond acceptors (HBA) and
donors (HBD). Afterwards, a matrix of compound descriptors with 1029 columns was con-
structed, in which each row represented a phytochemical, a CMap bioactive compound, or an
FDA-approved drug and a principle component analysis (PCA) using R was performed.
Retrieval of direct and indirect protein targets of phytochemicals. Phytochemicals were
mapped to exact InChI key matches in ChEMBL and similar ChEMBL compounds using the
Morgan circular fingerprint. The Tanimoto Coefficient (TC) was calculated based on Morgan
fingerprint. Two compounds were similar if TC0.85 and their difference in molecular weight
lower than 50 g/mol. Next, the interactions of phytochemicals and proteins were annotated by
searching in ChEMBL the protein targets of those exactly matched or similar ChEMBL com-
pounds. The bioactivities were filtered based on the following thresholds: for Ki, Kd, IC50 and
EC50, pchembl_value larger than 6; for inhibition, measurement value greater than 30%; for
potency, measurement value lower than 50 μM. To deal with the multiple measurements of the
same compound on the same protein, we calculated a frequency of “positive”measurements
(served as evidence of compound-protein interaction) among all candidate measurements.
Only chemical-protein interactions with a frequency of higher than 0.5 were considered confi-
dent and were used for further analysis. In addition to chemical-protein interactions from
ChEMBL, we also included first-degree protein-protein interaction (PPI) partners (a confi-
dence score higher than 400) from STRING 9.1 [21], in order to further expand our protein
target space of phytochemicals. Note that this was only done for the protein targets of phyto-
chemicals matching exactly to ChEMBL compounds. Only those PPI from human, rats and
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mice were included. After obtaining protein targets for phytochemicals, protein targets in rats
and mice were mapped to their human orthologous proteins through Ensembl Biomart Homo-
log Service [22].
Microarray data extraction and analysis. ArrayExpress database [23] was first queried
with a list of edible plants. Besides microarray data from human, experiments from rats and
mice were included. For each microarray dataset, the raw data were background-corrected and
normalized with RMA [24]. Quality check of the datasets was conducted in R with the array-
QualityMetrics package [25]. After manual inspection and quality check, 17 gene expression
microarray experiments remained for downstream analysis. Differential expression analysis of
pre-processed microarray data was performed with the R Bioconductor limma package [26]. A
p-value of 0.05 after false discovery rate (FDR) correction for multiple hypothesis testing was
used as the cutoff when selecting significantly differentially expressed (DE) genes [27]. Our
analysis resulted in 9 foods with significant gene expression signatures and available phyto-
chemical composition in NutriChem (see S5 Table). For each food, the list of DE genes was
split into two lists of up- and down-regulated genes, referred to as “tag lists” in Connectivity
Map [12]. The genes in the tag lists were converted to the CMap-compatible probe-set IDs
from Affymetrix GeneChip Human Genome U133A Array. For DE genes in rats and mice, the
human homolog genes were obtained through Ensembl Biomart Homolog Service [22] before
mapping to required probe-set IDs. The paired tag lists were used to query Connectivity Map
to reveal the correlation or anti-correlation relationship between foods and drugs. Based on the
output from Connectivity Map, CMap drugs or bioactive compounds were considered to cor-
relate or anti-correlate with foods if they had an absolute enrichment score higher than 0.75,
permutation p-value less than 0.01 and a non-null percentage above 80%.
Supporting Information
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number of common interacting proteins between two foods.
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(XLSX)
S5 Table. Microarray Datasets. 9 foods with significant gene expression signatures and known
phytochemical composition.
(XLSX)
Acknowledgments
GP would like to thank the University of Hong Kong (e-SRT on Integrative Biology)
for support.
Systems-wide Drug-Food Interactions
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004048 February 10, 2015 13 / 15
Author Contributions
Conceived and designed the experiments: GP IK. Performed the experiments: KJ YN. Analyzed
the data: KJ YN GP IK. Wrote the paper: KJ YN GP IK.
References
1. Chan L-N (2013) Drug-nutrient interactions. JPEN J Parenter Enteral Nutr 37: 450–459. doi: 10.1177/
0148607113488799 PMID: 23674575
2. YamreudeewongW, Henann NE, Fazio A, Lower DL, Cassidy TG (1995) Drug-food interactions in clini-
cal practice. J Fam Pract 40: 376–384. PMID: 7699352
3. Schmidt LE, Dalhoff K (2002) Food-drug interactions. Drugs 62: 1481–1502. PMID: 12093316
4. Seden K, Dickinson L, Khoo S, Back D (2010) Grapefruit-drug interactions. Drugs 70: 2373–2407. doi:
10.2165/11585250–000000000–00000 PMID: 21142260
5. Misaka S, Yatabe J, Müller F, Takano K, Kawabe K, et al. (2014) Green tea ingestion greatly reduces
plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. doi: 10.1038/clpt.2013.241
PMID: 25399714
6. Zhou S, Lim LY, Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36: 57–104.
doi: 10.1081/DMR-120028427 PMID: 15072439
7. Sacco SM, Chen J, Power KA, WardWE, Thompson LU (2008) Lignan-rich sesame seed negates the
tumor-inhibitory effect of tamoxifen but maintains bone health in a postmenopausal athymic mouse
model with estrogen-responsive breast tumors. Menopause 15: 171–179. doi: 10.1097/gme.
0b013e3180479901 PMID: 17545920
8. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, et al. (2014) The ChEMBL bioactivity database:
an update. Nucleic Acids Res 42: D1083–D1090. doi: 10.1093/nar/gkt1031 PMID: 24214965
9. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for
“omics” research on drugs. Nucleic Acids Res 39: D1035–D1041. doi: 10.1093/nar/gkq1126 PMID:
21059682
10. Jensen K, Panagiotou G, Kouskoumvekaki I (2014) Integrated text mining and chemoinformatics analy-
sis associates diet to health benefit at molecular level. PLoS Comput Biol 10: e1003432. doi: 10.1371/
journal.pcbi.1003432 PMID: 24453957
11. Jensen K, Panagiotou G, Kouskoumvekaki I (2014) NutriChem: a systems chemical biology resource
to explore the medicinal value of plant-based foods. Nucleic Acids Res. doi: 10.1093/nar/gku724.
12. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-ex-
pression signatures to connect small molecules, genes, and disease. Science 313: 1929–1935. doi:
10.1126/science.1132939 PMID: 17008526
13. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative
medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:
2505–2514. PMID: 10893280
14. Sparber A, Wootton JC, Bauer L, Curt G, Eisenberg D, et al. (2000) Use of complementary medicine by
adult patients participating in HIV/AIDS clinical trials. J Altern Complement Med 6: 415–422. PMID:
11059503
15. Hu Y-M, YeW-C, Yin Z-Q, Zhao S-X (2007) [Chemical constituents from flos Sesamum indicum L]. Yao
Xue Xue Bao 42: 286–291. PMID: 17520828
16. Chang F-R, Hayashi K, Chua N-H, Kamio S, Huang Z-Y, et al. (2005) The transgenic Arabidopsis plant
system, pER8-GFP, as a powerful tool in searching for natural product estrogen-agonists/antagonists.
J Nat Prod 68: 971–973. doi: 10.1021/np050121i PMID: 16038533
17. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for
facilitating target-oriented drug discovery. Nucleic acids research 40: D1128–D1136. doi: 10.1093/nar/
gkr797 PMID: 21948793
18. LePendu P, Musen MA, Shah NH (2011) Enabling enrichment analysis with the Human Disease Ontol-
ogy. J Biomed Inform 44 Suppl 1: S31–S38. doi: 10.1016/j.jbi.2011.04.007 PMID: 21550421
19. Bolton EE, Wang Y, Thiessen PA, Bryant SH (n.d.) PubChem: Integrated Platform of Small Molecules
and Biological Activities. Annual Reports in Computational Chemistry 4.
20. Berthold MR, Cebron N, Dill F, Gabriel TR, Kötter T, et al. (2008) KNIME: The Konstanz Information
Miner. In: Preisach C, Burkhardt PDH, Schmidt-Thieme PDL, Decker PDR, editors. Data Analysis, Ma-
chine Learning and Applications. Studies in Classification, Data Analysis, and Knowledge Organiza-
tion. Springer Berlin Heidelberg. pp. 319–326. Available: http://link.springer.com.globalproxy.cvt.dk/
chapter/10.1007/978-3-540-78246-9_38. Accessed 22 May 2014.
Systems-wide Drug-Food Interactions
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004048 February 10, 2015 14 / 15
21. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, et al. (2013) STRING v9.1: protein-
protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808–
D815. doi: 10.1093/nar/gks1094 PMID: 23203871
22. Flicek P, Amode MR, Barrell D, Beal K, Billis K, et al. (2014) Ensembl 2014. Nucleic Acids Res 42:
D749–D755. doi: 10.1093/nar/gkt1196 PMID: 24316576
23. Rustici G, Kolesnikov N, Brandizi M, Burdett T, Dylag M, et al. (2013) ArrayExpress update—trends in
database growth and links to data analysis tools. Nucleic Acids Res 41: D987–D990. doi: 10.1093/nar/
gks1174 PMID: 23193272
24. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normaliza-
tion, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264.
doi: 10.1093/biostatistics/4.2.249 PMID: 12925520
25. Kauffmann A, Gentleman R, Huber W (2009) arrayQualityMetrics—a bioconductor package for quality
assessment of microarray data. Bioinformatics 25: 415–416. doi: 10.1093/bioinformatics/btn647
PMID: 19106121
26. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in
microarray experiments. Stat Appl Genet Mol Biol 3: Article3. doi: 10.2202/1544–6115.1027 PMID:
16646824
27. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful
Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57:
289–300. doi: 10.2307/2346101.
Systems-wide Drug-Food Interactions
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004048 February 10, 2015 15 / 15
